GlassScriptPhysician profile
Taylor Stuart Campbell
NPI 1760048987
$8,756.70
in general payments reported to CMS, 2019-2025
38 companies · $6,119 in 2025
The $6,119 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.09 · 2020: $52.05 · 2021: $205 · 2022: $645 · 2023: $387 · 2024: $1,283 · 2025: $6,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,036 · Consulting Fee: $1,525 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,220 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,035.65 |
| Consulting Fee | $1,525.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,220.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,000.75 | 2024-2025 | |
| Abbvie INC. | $2,749.55 | 2021-2025 | Botox, Ubrelvy |
| Neurocrine Biosciences, INC. | $476.41 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $357.73 | 2022-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $201.28 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $199.94 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $182.30 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $180.96 | 2021-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $165.35 | 2024-2025 | Hyqvia |
| Genentech USA, INC. | $145.45 | 2022-2025 | Enspryng, Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $132.45 | 2020-2023 | Xcopri |
| Amgen INC. | $103.78 | 2022-2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $77.62 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $72.74 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $66.58 | 2025 | Austedo Xr, Ajovy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $60.47 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $59.04 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $54.02 | 2022-2023 | Trudhesa |
| Ucb, INC. | $42.53 | 2019-2025 | Briviact |
| Kyowa Kirin, INC. | $42.14 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $31.92 | 2025 | Motpoly Xr |
| Horizon Therapeutics Plc | $29.96 | 2021 | |
| Gilead Sciences, INC. | $26.60 | 2024 | |
| Emd Serono, INC. | $26.20 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.28 | 2025 | Amvuttra |
| Janssen Biotech, INC. | $24.21 | 2025 | |
| Biogen, INC. | $24.13 | 2025 | Spinraza, Qalsody |
| Csl Behring | $21.59 | 2024 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $21.14 | 2025 | |
| Eisai INC. | $19.62 | 2024 | |
| Mallinckrodt Hospital Products INC. | $19.08 | 2021 | |
| Boston Scientific Corporation | $18.02 | 2024 | |
| Ns Pharma, INC. | $18.01 | 2025 | Viltepso |
| Tanabe Pharma America, INC. | $17.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.38 | 2019 | |
| Acorda Therapeutics, INC | $16.30 | 2019 | |
| Celgene Corporation | $14.89 | 2020 | |
| Neurelis, INC. | $13.57 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.